Results 281 to 290 of about 89,124 (355)

Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis ‐ To Suppress or Not to Suppress?

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 7, Page 897-918, October 2026.
Individualized assessment identifies patients with decompensated autoimmune hepatitis cirrhosis who are likely to benefit from a time‐limited trial of immunosuppression versus those requiring immediate liver transplant evaluation. Early objective response monitoring (bilirubin, MELD‐Na and AST/ALT) guides continuation of immunosuppression, promotes ...
Pedro Robson Costa Passos   +2 more
wiley   +1 more source

IMPROVE 2025: The 3rd International Meeting on Pathway‐Related Obesity: Vision & Evidence

open access: yesClinical Obesity, Volume 16, Issue 5, October 2026.
ABSTRACT An international cohort of 161 clinicians and researchers from 19 countries attended the 3rd International Meeting on Pathway‐Related Obesity: Vision & Evidence (IMPROVE) in Prague, Czech Republic, on 2–4 July 2025. The aims of the meeting were to advance understanding of hyperphagia and obesity caused by defects in the melanocortin‐4 receptor
Jesús Argente   +17 more
wiley   +1 more source

Discovery of Epidermal Growth Factor‐Like 7 as a Potential Non‐Invasive Biomarker for Fibrosis and Mortality Risk in MASLD

open access: yesClinical and Translational Science, Volume 19, Issue 10, October 2026.
Proteomic discovery and validation of EGFL7 as a potential non‐invasive biomarker in MASLD. EGFL7 was identified as the top‐ranked proteomic feature in a clinical cohort, demonstrated diagnostic performance comparable to FIB‐4 for fibrosis assessment, and was associated with increased all‐cause mortality risk in the UK Biobank.
Heather Collis   +11 more
wiley   +1 more source

Splenic shear wave elastography beyond portal hypertension: a narrative review of non-portal applications. [PDF]

open access: yesJ Ultrason
Paratore M   +13 more
europepmc   +1 more source

Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice

open access: yesJournal of Internal Medicine, Volume 300, Issue 4, Page 440-460, October 2026.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and a leading cause of cirrhosis, hepatocellular carcinoma, and cardiometabolic morbidity. Often clinically silent until advanced fibrosis develops, management has largely relied on lifestyle interventions, with limited ...
Philip N. Newsome, Saima Ajaz
wiley   +1 more source

Home - About - Disclaimer - Privacy